Innoviva Statistics
Total Valuation
Innoviva has a market cap or net worth of $1.73 billion. The enterprise value is $1.47 billion.
| Market Cap | 1.73B |
| Enterprise Value | 1.47B |
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Innoviva has 74.05 million shares outstanding. The number of shares has increased by 14.25% in one year.
| Current Share Class | 74.05M |
| Shares Outstanding | 74.05M |
| Shares Change (YoY) | +14.25% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 0.80% |
| Owned by Institutions (%) | 100.05% |
| Float | 69.23M |
Valuation Ratios
The trailing PE ratio is 7.08 and the forward PE ratio is 11.49. Innoviva's PEG ratio is 0.32.
| PE Ratio | 7.08 |
| Forward PE | 11.49 |
| PS Ratio | 4.14 |
| Forward PS | 3.81 |
| PB Ratio | 1.46 |
| P/TBV Ratio | 1.75 |
| P/FCF Ratio | 8.70 |
| P/OCF Ratio | 8.65 |
| PEG Ratio | 0.32 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.53, with an EV/FCF ratio of 7.50.
| EV / Earnings | 5.41 |
| EV / Sales | 3.57 |
| EV / EBITDA | 7.53 |
| EV / EBIT | 8.71 |
| EV / FCF | 7.50 |
Financial Position
The company has a current ratio of 14.64, with a Debt / Equity ratio of 0.28.
| Current Ratio | 14.64 |
| Quick Ratio | 13.28 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | 1.69 |
| Interest Coverage | 10.10 |
Financial Efficiency
Return on equity (ROE) is 29.09% and return on invested capital (ROIC) is 16.10%.
| Return on Equity (ROE) | 29.09% |
| Return on Assets (ROA) | 7.18% |
| Return on Invested Capital (ROIC) | 16.10% |
| Return on Capital Employed (ROCE) | 10.63% |
| Weighted Average Cost of Capital (WACC) | 6.16% |
| Revenue Per Employee | $2.59M |
| Profits Per Employee | $1.71M |
| Employee Count | 159 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 2.83 |
Taxes
In the past 12 months, Innoviva has paid $55.70 million in taxes.
| Income Tax | 55.70M |
| Effective Tax Rate | 17.04% |
Stock Price Statistics
The stock price has increased by +27.39% in the last 52 weeks. The beta is 0.42, so Innoviva's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +27.39% |
| 50-Day Moving Average | 21.96 |
| 200-Day Moving Average | 20.21 |
| Relative Strength Index (RSI) | 63.20 |
| Average Volume (20 Days) | 781,690 |
Short Selling Information
The latest short interest is 6.82 million, so 9.20% of the outstanding shares have been sold short.
| Short Interest | 6.82M |
| Short Previous Month | 6.66M |
| Short % of Shares Out | 9.20% |
| Short % of Float | 9.85% |
| Short Ratio (days to cover) | 6.61 |
Income Statement
In the last 12 months, Innoviva had revenue of $411.33 million and earned $271.17 million in profits. Earnings per share was $3.30.
| Revenue | 411.33M |
| Gross Profit | 308.23M |
| Operating Income | 168.59M |
| Pretax Income | 326.86M |
| Net Income | 271.17M |
| EBITDA | 194.99M |
| EBIT | 168.59M |
| Earnings Per Share (EPS) | $3.30 |
Balance Sheet
The company has $566.67 million in cash and $331.25 million in debt, with a net cash position of $235.42 million or $3.18 per share.
| Cash & Cash Equivalents | 566.67M |
| Total Debt | 331.25M |
| Net Cash | 235.42M |
| Net Cash Per Share | $3.18 |
| Equity (Book Value) | 1.17B |
| Book Value Per Share | 15.71 |
| Working Capital | 677.82M |
Cash Flow
In the last 12 months, operating cash flow was $196.93 million and capital expenditures -$1.13 million, giving a free cash flow of $195.80 million.
| Operating Cash Flow | 196.93M |
| Capital Expenditures | -1.13M |
| Depreciation & Amortization | 26.41M |
| Net Borrowing | -25,000 |
| Free Cash Flow | 195.80M |
| FCF Per Share | $2.64 |
Margins
Gross margin is 74.94%, with operating and profit margins of 40.99% and 65.92%.
| Gross Margin | 74.94% |
| Operating Margin | 40.99% |
| Pretax Margin | 79.47% |
| Profit Margin | 65.92% |
| EBITDA Margin | 47.41% |
| EBIT Margin | 40.99% |
| FCF Margin | 47.60% |
Dividends & Yields
Innoviva does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.25% |
| Shareholder Yield | -14.25% |
| Earnings Yield | 15.92% |
| FCF Yield | 11.50% |
Analyst Forecast
The average price target for Innoviva is $32.80, which is 40.47% higher than the current price. The consensus rating is "Buy".
| Price Target | $32.80 |
| Price Target Difference | 40.47% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 5.49% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Innoviva has an Altman Z-Score of 2.92 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.92 |
| Piotroski F-Score | 5 |